5077472025-10-012025-12-315077472025-12-315077472025-04-012025-12-315077472025-10-012025-12-31in-capmkt:OtherExpenses1Member5077472025-04-012025-12-31in-capmkt:OtherExpenses1Member5077472025-10-012025-12-31in-capmkt:ReportableSegments1Member5077472025-10-012025-12-31in-capmkt:ReportableSegments2Member5077472025-10-012025-12-31in-capmkt:ReportableSegments3Member5077472025-10-012025-12-31in-capmkt:ReportableSegments4Member5077472025-10-012025-12-31in-capmkt:ReportableSegments5Member5077472025-10-012025-12-31in-capmkt:ReportableSegments6Member5077472025-04-012025-12-31in-capmkt:ReportableSegments1Member5077472025-04-012025-12-31in-capmkt:ReportableSegments2Member5077472025-04-012025-12-31in-capmkt:ReportableSegments3Member5077472025-04-012025-12-31in-capmkt:ReportableSegments4Member5077472025-04-012025-12-31in-capmkt:ReportableSegments5Member5077472025-04-012025-12-31in-capmkt:ReportableSegments6Member5077472025-10-012025-12-31in-capmkt:ReportableSegments1Member5077472025-10-012025-12-31in-capmkt:ReportableSegments2Member5077472025-10-012025-12-31in-capmkt:ReportableSegments3Member5077472025-10-012025-12-31in-capmkt:ReportableSegments4Member5077472025-10-012025-12-31in-capmkt:ReportableSegments5Member5077472025-10-012025-12-31in-capmkt:ReportableSegments6Member5077472025-04-012025-12-31in-capmkt:ReportableSegments1Member5077472025-04-012025-12-31in-capmkt:ReportableSegments2Member5077472025-04-012025-12-31in-capmkt:ReportableSegments3Member5077472025-04-012025-12-31in-capmkt:ReportableSegments4Member5077472025-04-012025-12-31in-capmkt:ReportableSegments5Member5077472025-04-012025-12-31in-capmkt:ReportableSegments6Member5077472025-10-012025-12-31in-capmkt:ReportableSegments1Member5077472025-12-31in-capmkt:ReportableSegments1Member5077472025-10-012025-12-31in-capmkt:ReportableSegments2Member5077472025-12-31in-capmkt:ReportableSegments2Member5077472025-10-012025-12-31in-capmkt:ReportableSegments3Member5077472025-12-31in-capmkt:ReportableSegments3Member5077472025-10-012025-12-31in-capmkt:ReportableSegments4Member5077472025-12-31in-capmkt:ReportableSegments4Member5077472025-10-012025-12-31in-capmkt:ReportableSegments5Member5077472025-12-31in-capmkt:ReportableSegments5Member5077472025-10-012025-12-31in-capmkt:ReportableSegments6Member5077472025-12-31in-capmkt:ReportableSegments6Member5077472025-10-012025-12-31in-capmkt:ReportableSegments1Member5077472025-12-31in-capmkt:ReportableSegments1Member5077472025-10-012025-12-31in-capmkt:ReportableSegments2Member5077472025-12-31in-capmkt:ReportableSegments2Member5077472025-10-012025-12-31in-capmkt:ReportableSegments3Member5077472025-12-31in-capmkt:ReportableSegments3Member5077472025-10-012025-12-31in-capmkt:ReportableSegments4Member5077472025-12-31in-capmkt:ReportableSegments4Member5077472025-10-012025-12-31in-capmkt:ReportableSegments5Member5077472025-12-31in-capmkt:ReportableSegments5Member5077472025-10-012025-12-31in-capmkt:ReportableSegments6Member5077472025-12-31in-capmkt:ReportableSegments6Member5077472025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15077472025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares507747TTKHLTCARENOTLISTEDINE910C01018TTK HEALTHCARE LIMITEDMain BoardEquity2025-04-012026-03-312026-01-222026-01-02INRLakhsQuarterlyThird quarterMulti segment2026-01-2212:00:002026-01-2213:00:00Not applicablefalsefalseDefault on Loans and Debt Securities is not Applicable to the Company2025-10-012025-12-31UnauditedStandalone20929890001743340002267323000513818000539558000-772240004172860006832000222150006281800002050665000216658000-7578700014087100044000000-84550003554500001053260000000105326000-3472000101854000141303000107.457.45007.457.45Notes <BR> 1 The above financial results for the Third Quarter and Period ended December 31 2025 in respect of TTK Healthcare Limited (the Company) have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on January 22 2026 at the Registered Office of the Company also with the provision of Video Conferencing facility <BR> <BR> 2 The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 <BR> <BR> 3 Significant Financial Events: <BR> <BR> a During the First Quarter of the previous year the Company had sold Leasehold land with building at Mahindra World City Chennai for a consideration of Rs 2300 lakhs and the profit on sale amounting to Rs 197705 lakhs (Net) has been considered in the above results <BR> <BR> b During the Fourth Quarter of the previous year the Company had written off the entire value of Male Contraceptives pertaining to the Protective Devices Division amounting to Rs 58639 lakhs that were meant for export under USAID Program owing to a 90-day pause on foreign development assistance and subsequent cancellation of Purchase Orders as the inventory was custom-made and not marketable to alternate buyers <BR> <BR> c On November 21 2025 the Government of India notified the four Labour Codes consolidating 29 existing labour laws and the Ministry of Labour & Employment subsequently issued draft Central Rules and FAQs Based on the best information presently available and in line with the guidance issued by the Institute of Chartered Accountants of India the Company has assessed the incremental impact arising from the change in the definition of wages and considering its material regulatory-driven and non-recurring nature has presented the same as Exceptional items in the Statement of Profit and Loss for the period ended December 31 2025 The incremental impact comprises of Gratuity of Rs 82302 lakhs and Long-term Compensated Absences of Rs 28485 lakhs against which a provision of Rs 350 lakhs created in the Fourth Quarter of FY 2020–21 has been adjusted resulting in a net charge of Rs 75787 lakhs recognised in the Current Quarter The Company is also evaluating other potential impacts of the Labour Codes including those relating to the contract workforce; however in the absence of final Central and State Rules and further regulatory clarifications such impacts cannot be reasonably estimated at this stage and their quantum and materiality remain indeterminate <BR> <BR> 4 The tax relating to earlier years represents the tax refund relating to AY 2016-17 & AY 2017-18 received consequent to completion of assessments <BR> <BR> 5 The Company does not have any Subsidiary Associate Joint Venture Company(ies) as on December 31 2025 <BR> <BR> 6 The previous period's year's figures have been regrouped and reclassified wherever necessary to conform to the current period's year's presentation <BR> <BR> 7 This statement is also available on the website of BSE Limited (www bseindia com) National Stock Exchange of India Limited (www nseindia com) and also on the website of the Company (www ttkhealthcare com)2025-04-012025-12-31UnauditedStandalone6392964000543819000693678300014899720001497570000-146960001241676000229120006621400020269730006330621000606162000-7578700053037500097848000-6657000911910000439184000000043918400042680004434520001413030001031.0831.080031.0831.08Other Expenses628180000Other Expenses2026973000ANIMAL WELFARE379121000CONSUMER PRODUCTS554105000MEDICAL DEVICES255414000PROTECTIVE DEVICES539858000FOODS363380000OTHERS1111000ANIMAL WELFARE1052702000CONSUMER PRODUCTS1873127000MEDICAL DEVICES799794000PROTECTIVE DEVICES1555234000FOODS1109070000OTHERS30370002092989000639296400020929890006392964000ANIMAL WELFARE39554000CONSUMER PRODUCTS22518000MEDICAL DEVICES49250000PROTECTIVE DEVICES-11023000FOODS33978000OTHERS1269000ANIMAL WELFARE94659000CONSUMER PRODUCTS130637000MEDICAL DEVICES190498000PROTECTIVE DEVICES-167941000FOODS101405000OTHERS3125000135546000352383000683200022912000-12157000-200904000140871000530375000ANIMAL WELFARE465950000CONSUMER PRODUCTS419840000MEDICAL DEVICES841359000PROTECTIVE DEVICES1313693000FOODS600053000OTHERS295570003670452000945605100013126503000ANIMAL WELFARE311205000CONSUMER PRODUCTS484786000MEDICAL DEVICES162381000PROTECTIVE DEVICES367234000FOODS165986000OTHERS1334700015049390006689340002173873000Notes <BR> 1 Segments have been identified in line with the Indian Accounting Standard on Segment Reporting (Ind AS 108) based on review of performance by the Top Management. <BR> 2 Details of products included in each of the Segments are as below <BR> Animal Welfare comprise products for Veterinary use. <BR> Consumer Products comprise marketing and distribution of Woodward's Gripewater, EVA Range of Cosmetics, Good Home range of Scrubbers, Air Fresheners, etc. <BR> Medical Devices include Artificial Heart Valves, Orthopaedic Implants, etc. <BR> Protective Devices comprise manufacturing and marketing of Male Contraceptives and other allied products. <BR> Foods comprise manufacturing and marketing of Food Products. <BR> Others include Printing and Publishing of Maps and Atlases <BR> 3 The segmentwise revenue, results, assets and liabilities figures relate to respective amounts directly identifiable to each of the segments. The unallocable expenditure includes expenses incurred on common services at the corporate level and also those expenses not identifiable to any specific segment. <BR> 4. The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation. <BR> Item that will not be reclassified subsequently to profit or loss-3608000-3608000Item that will not be reclassified subsequently to profit or loss44310004431000-13600016300000-34720004268000